These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 10563213)
1. Responsiveness of the Scripps neurologic rating scale during a multiple sclerosis clinical trial. Koziol JA; Lucero A; Sipe JC; Romine JS; Beutler E Can J Neurol Sci; 1999 Nov; 26(4):283-9. PubMed ID: 10563213 [TBL] [Abstract][Full Text] [Related]
2. A comparison of two neurologic scoring instruments for multiple sclerosis. Koziol JA; Frutos A; Sipe JC; Romine JS; Beutler E J Neurol; 1996 Mar; 243(3):209-13. PubMed ID: 8936349 [TBL] [Abstract][Full Text] [Related]
3. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Rice GP; Filippi M; Comi G Neurology; 2000 Mar; 54(5):1145-55. PubMed ID: 10720289 [TBL] [Abstract][Full Text] [Related]
4. Comparative evaluations of neuroperformance and clinical outcome assessments in chronic progressive multiple sclerosis: I. Reliability, validity and sensitivity to disease progression. Multiple Sclerosis Study Group. Syndulko K; Ke D; Ellison GW; Baumhefner RW; Myers LW; Tourtellotte WW Mult Scler; 1996 Oct; 2(3):142-56. PubMed ID: 9345379 [TBL] [Abstract][Full Text] [Related]
5. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Leist TP; Comi G; Cree BA; Coyle PK; Freedman MS; Hartung HP; Vermersch P; Casset-Semanaz F; Scaramozza M; Lancet Neurol; 2014 Mar; 13(3):257-67. PubMed ID: 24502830 [TBL] [Abstract][Full Text] [Related]
9. Development of cladribine treatment in multiple sclerosis. Sipe JC; Romine JS; Koziol JA; McMillan R; Zyroff J; Beutler E Mult Scler; 1996 Jul; 1(6):343-7. PubMed ID: 9345414 [TBL] [Abstract][Full Text] [Related]
10. Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study. Stelmasiak Z; Solski J; Nowicki J; Jakubowska B; Ryba M; Grieb P Mult Scler; 2009 Jun; 15(6):767-70. PubMed ID: 19482866 [TBL] [Abstract][Full Text] [Related]
11. A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis. Walker JE; Giri SN; Margolin SB Mult Scler; 2005 Apr; 11(2):149-58. PubMed ID: 15794387 [TBL] [Abstract][Full Text] [Related]
12. Assessing information in T2-weighted MRI scans from secondary progressive MS patients. Koziol JA; Wagner S; Adams HP Neurology; 1998 Jul; 51(1):228-33. PubMed ID: 9674807 [TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Cook S; Vermersch P; Comi G; Giovannoni G; Rammohan K; Rieckmann P; Sørensen PS; Hamlett A; Miret M; Weiner J; Viglietta V; Musch B; Greenberg SJ; Mult Scler; 2011 May; 17(5):578-93. PubMed ID: 21228029 [TBL] [Abstract][Full Text] [Related]
14. Mitoxantrone: a review of its use in multiple sclerosis. Scott LJ; Figgitt DP CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110 [TBL] [Abstract][Full Text] [Related]
15. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis. Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540 [TBL] [Abstract][Full Text] [Related]
16. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S; Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565 [TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of subcutaneous cladribine therapy in progressive multiple sclerosis. Selby R; Brandwein J; O'Connor P Can J Neurol Sci; 1998 Nov; 25(4):295-9. PubMed ID: 9827230 [TBL] [Abstract][Full Text] [Related]
18. Treatment of multiple sclerosis and other autoimmune diseases with cladribine. Beutler E; Sipe J; Romine J; McMillan R; Zyroff J; Koziol J Semin Hematol; 1996 Jan; 33(1 Suppl 1):45-52. PubMed ID: 8714617 [No Abstract] [Full Text] [Related]
19. Whole brain volume changes in patients with progressive MS treated with cladribine. Filippi M; Rovaris M; Iannucci G; Mennea S; Sormani MP; Comi G Neurology; 2000 Dec; 55(11):1714-8. PubMed ID: 11113227 [TBL] [Abstract][Full Text] [Related]
20. The psychometric properties of clinical rating scales used in multiple sclerosis. Sharrack B; Hughes RA; Soudain S; Dunn G Brain; 1999 Jan; 122 ( Pt 1)():141-59. PubMed ID: 10050902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]